September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Steroid sparing effect of 0.1% tacrolimus eye drops for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases
Author Affiliations & Notes
  • Dai Miyazaki
    Ophthalmology, Tottori University, Yonago, Tottori, Japan
  • Atsuki Fukushima
    Kochi Medical School, Kochi , Japan
  • Yuichi Ohashi
    Ehime University School of Medicine, Ehime, Japan
  • Nobuyuki Ebihara
    Juntendo University School of Medicine, Tokyo, Japan
  • Eiichi Uchio
    Fukuoka University, Fukuoka, Japan
  • Shigeki Okamoto
    Okamoto Eye Clinic, Ehime, Japan
  • Jun Shoji
    Nihon University School of Medicine, Tokyo, Japan
  • Etsuko Takamura
    Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
  • Yayoi Nakagawa
    Nakagawa Eye Clinic, Osaka, Japan
  • Kenichi Namba
    Hokkaido University Graduate School of Medicine, Hokkaido, Japan
  • Hiroshi Fujishima
    Tsurumi University Dental Hospital, Kanagawa, Japan
  • Footnotes
    Commercial Relationships   Dai Miyazaki, None; Atsuki Fukushima, None; Yuichi Ohashi, None; Nobuyuki Ebihara, None; Eiichi Uchio, None; Shigeki Okamoto, None; Jun Shoji, None; Etsuko Takamura, None; Yayoi Nakagawa, None; Kenichi Namba, None; Hiroshi Fujishima, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 303. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dai Miyazaki, Atsuki Fukushima, Yuichi Ohashi, Nobuyuki Ebihara, Eiichi Uchio, Shigeki Okamoto, Jun Shoji, Etsuko Takamura, Yayoi Nakagawa, Kenichi Namba, Hiroshi Fujishima; Steroid sparing effect of 0.1% tacrolimus eye drops for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases. Invest. Ophthalmol. Vis. Sci. 2016;57(12):303.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate steroid sparing effect of 0.1% tacrolimus eye drops for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases.

Methods : Clinical findings from the multi-center study involving 761 eyes of 761 patients with shield ulcer or corneal epitheliopathy were retrospectively analyzed. Of them, 231 patients were shield ulcer. All the patients were treated with tacrolimus eye drops, and 399 patients (52%) necessitated with topical steroids in conjunction during the 3 months follow up. Clinical signs were rated on a 4 grade scale. For corneal epitheliopathy, no corneal staining was 0, and shield ulcer was 3 as highest.

Results : The mean epitheliopathy score at baseline was 2.02± 0.80 (SD) for steroid-treated patients, and 1.80±0.82 for patients without steroids. After 1 month of tacrolimus treatment, epitheliopathy score significantly reduced to 0.86±0.97 and 0.63±0.88, respectively. For shield ulcer patients, epitheliopathy score significantly reduced to 1.45±1.13 and 1.39±1.18, respectively. No significant difference by steroid use was observed.
To assess score reduction effect of topical tacrolimus and steroids for epitheliopathy, multi-level linear regression analysis was conducted. Tacrolimus eye drops significantly reduced score by 1.36 (P<0.0005) within 1 month after adjustment of age, giant papilla score and steroid use. In contrast, reduction effect of topical steroid was minimal and insignificant (0.09 for fluorometholone, and -0.06 for betamethasone).

Conclusions : Tacrolimus eye drops had significant steroid sparing effect for treatment of shield ulcer or epitheliopathy, and allow non-steroidal therapy for management of shield ulcer and corneal epitheliopathy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×